Imugene Ltd at JPMorgan Healthcare Conference Transcript
Good afternoon, and welcome, everyone. It's my great pleasure on behalf of JP Morgan to welcome Imugene to today's session. So our presenting will be Leslie Chong, Managing Director and CEO of Imugene, and I'll do it with her. Thank you.
Hello. My name is Leslie Chong, I'm the CEO and MD of Imugene, it's a great honor to speak to you all today regarding the company. And my disclaimer. So Imugene as a snapshot, our market cap is AUD860 million however, I think we're a little bit higher today. Our goal is to get over AUD1 billion, of course. Cash runway as of September last quarter was around AUD163 million, so it's quite a wonderful runway to develop our four platform technology. We have a cellular therapy as well as an Oncolytic Virus, and on OnCARlytics, I'll go into that in just a little bit, and our B Cell immunotherapy cancer vaccines.
We have an in-house GMP cell therapy manufacturing facility in Durham, North Carolina, and we are in solid tumors as well as now well into blood
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
